Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Ascelia Pharma, Audiocast, Q4'25

By Inderes2/5/2026, 9:00 AM
Ascelia Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Magnus Corfitzen
00:00 - 04:50

Welcome, everyone, to the webcast for Ascelia Pharma Q4 report for 2025. On this call, we will be making forward-looking statements. On today's call, we will start with an overview of Ascelia Pharma's recent key events and then head into the portfolio update before moving on to financials and priorities ahead. After the presentation, we will open up for questions. As usual, I'm Magnus Corfitzen, CEO of Ascelia Pharma, and with me today I have Julie Waras Brogren, Deputy CEO, Andreas Norlin, Chief Scientific Officer, and Anton Hansson, CFO. I'm pleased to welcome Anton to his first quarterly call as Chief Financial Officer. This will also be the last quarterly call with Julie, as she will be moving on to new opportunities, as we announced a few weeks ago. At Ascelia Pharma, we identify, develop, and commercialize novel drugs that address unmet medical needs across rare cancer conditions. We're based in Malmö, Sweden, and are listed on Nasdaq Stockholm. We have two drugs in our pipeline. Orviglance is a diagnostic drug that is now under FDA review with the PDUFA date of July 3rd this year. We will spend the majority of this call talking about Orviglance. Oncoral is a patented tablet formulation of Irinotecan, with encouraging results in Phase 1 and potential to treat a range of solid tumors. We are very excited about Orviglance, and here's why. Orviglance is addressing a well-defined unmet medical need for a subgroup of people living with cancer. This translates into an $800 million addressable global market opportunity, and Orviglance is a first-in-class product to target this market and has Orphan Drug Designation from the FDA. We have commercial-scale manufacturing in place, and we have strong data from nine different clinical studies, including very compelling Phase 3 data. As mentioned, the Orviglance New Drug Application has been submitted to the FDA, and the review process is ongoing. The key milestone in the fourth quarter of 2025 was the FDA acceptance of the Orviglance NDA. In mid-November, the Day 74 letter was received. This means that the FDA has reviewed the NDA file and decided it has the quality that warrants a full review. The FDA has also set a PDUFA date of July 3rd this year. This is the date when they expect to have made a decision on approval. In Q4, we submitted a new patent application for manufacturing of Orviglance, which may extend the exclusivity period for Orviglance. In November, we announced the appointment of Anton Hansson as our new Chief Financial Officer, and he started a few weeks ago. Anton has a background in corporate finance and most recently worked with KPMG. I'm very happy to have him join our team. The long-term incentive program of 2022 vested, and 53,000 shares were awarded in November to employees who had purchased and held the shares throughout the three-year period. Also in Q4, the nomination committee was appointed by the largest shareholders in Ascelia Pharma. After the close of the quarter earlier this January, we announced that Julie will be leaving Ascelia Pharma, and I would like to thank her for her contributions to Ascelia throughout the years and wish her best of luck in her new role. There are two major value-creating milestones for Orviglance, and we are on track to meet both of them. The first objective is the FDA approval of Orviglance, and the key milestone of this is the submission we made in September last year. In mid-November, the FDA set a date, which is July 3rd this year. And this is, as mentioned, the date when they expect to make a decision on approval, and activities for the NDA review, including the interactions with the FDA, are progressing well, and we continue to be on track for approval. The second objective is to progress Orviglance for commercialization. This is a two-pronged approach. One is to continue our work to advance launch readiness by ensuring manufacturing and supply chain is as ready for launch as possible, as well as working with medical experts and including key opinion leaders, payers and other key stakeholders. The other track that we are also working on is to make a deal with a partner who will drive the commercialization. Julie will follow up on our progress there. I'm very happy with the progress we are making on these important milestones, and I'm optimistic for a very strong 2026. For Ascelia Pharma. We will start the portfolio section of our presentation with Orviglance. And I'll hand over to Julie.

Julie Waras Brogren
04:51 - 11:13

Thank you. Orviglance is a first-in-class Liver MRI contrast agent, which addresses an unmet medical need for cancer patients for whom there are no good alternatives available today. Liver metastases are common in many cancer types, and adequate visualization of liver tumors and metastases is critical for making timely and appropriate treatment decisions. Orviglance, based on Manganese, aims to be the preferred liver magnetic resonance imaging contrast agent for patients with severe kidney impairment. These patients have the highest risk of developing the serious and potentially fatal condition nephrogenic systemic fibrosis after exposure to the gadolinium-based contrast agents normally used today. The addressable market for Orviglance has a global value of $800 million annually. The US represents almost half of this. This market opportunity for Orviglance addresses the unmet need for a well-defined patient population of cancer patients who need imaging of their liver and who also have severely impaired kidney function. Our commercialization strategy is to launch through partners. This supports our ambition to secure the optimal balance between future revenues and investment required. Our focused, ambitious launch strategy and plans are built on advanced market insights and are already in place to support this partnering strategy and launch. As mentioned, the US is the largest commercial opportunity for Orviglance in the US alone. Our real-world data, i.e. Data from realized procedures in our target patient population show that every year 100,000 abdominal imaging procedures are performed in around 50,000 patients that fall under the black box warning for gadolinium contrast agents, i.e. Our target patient population. This is about 4% of people with cancer undergoing abdominal imaging. The well-defined patient population with a clear unmet need also drives an attractive pricing opportunity, and we have extensive input from market access and pricing experts, with whom we have tested different pricing levels and collected insights on the evidence needed to support access and reimbursement. And we have investigated pricing and access benchmarks of other innovative diagnostic drugs in the US, and 90% of healthcare professionals are concerned with issues related to Gadolinium contrast agents, including the severe side effect associated with our target patient population, NSF; in fact, 16% of providers have experienced cases of NSF in patients exposed to Gadolinium. When speaking with experts, whether in radiology or nephrology, they confirm that an alternative to Gadolinium for our target patient population would address concerns of today, with the potential to become a valuable addition to their clinical practice, and the momentum for options for patients without Gadolinium is strong. Beyond the risk of NSF in kidney-impaired patients, Gadolinium is well known to be retained in the brain and other tissue in all patients, and scrutiny over the possible safety effects is a key concern of regulators and medical bodies. It's also well known that gadolinium is excreted via the kidneys in urine, and because it's difficult to remove in our sewage system. It's discharged into the environment and into our drinking water. There's an urgency from regulators and medical bodies to find a viable alternative to the growing use of toxic Gadolinium, an alternative that is not associated with these potential safety and environmental concerns for patients and for the environment. While Gadolinium presents challenges, the industry is responding, and Orviglance will be the first-in-class liver MRI contrast agent for a future with less gadolinium and improved outcomes for patients. Recent developments from other large Gadolinium manufacturers are focused on an early-stage injectable manganese-based contrast agent, which is not liver-specific like Orviglance, or focused on smaller doses of gadolinium. And we are excited that we have a head start with the upcoming approval and launch of Orviglance. The go-to-market strategy for Orviglance is to launch with commercialization partners. The strategy supports our objective to maximize the value of Orviglance. Orviglance is an attractive partnering opportunity. With clinical development completed, we offer a de-risked asset which is on track for FDA approval this summer. There is a clear unmet need for a focused launch with a well-defined patient population. So there are synergies for many types of commercial stage companies working with hospital decision makers. Partnering dialogues progress with additional momentum and clarity. Now, with the regulatory timeline firmly established. In summary, we are excited about the opportunity to bring Orviglance to approval and to market with a partner, a market representing 800 million USD annually in addressable market for an unmet need of a very vulnerable patient population. We've come a long way with the successful completion of clinical development, and our data supporting the efficacy and safety of Orviglance was well-received by the medical community. I will hand it over to Andreas to talk about the timeline and the review process with the FDA.

Andreas Norlin
11:15 - 17:03

Thank you very much, Julie. I would like to start with a few highlights from the development program of Orviglance. We have a quite extensive clinical development program, including a total of 286 patients and healthy volunteers across nine clinical studies. And together, these studies have shown a strong, consistent positive benefit-risk profile, supporting the intended use in patients in need of a Liver MRI and with severe renal impairment. The Phase 3 SPARKLE study demonstrated that visualization of focal liver lesions, measured by the co-primary efficacy variables border delineation and lesion contrast, clearly improved with Orviglance compared to unenhanced imaging with a high degree of statistical significance. We could also see that more lesions, especially smaller ones, could be detected in the liver with Orviglance than without. In summary, with this strong data package supporting the use of Orviglance in a patient population with a unique and well-defined medical need, the NDA was, as we have heard before, successfully submitted and accepted for filing by the FDA last year. And now we are very excited that the FDA is proceeding with a review as planned, according to their internal schedule and with the target of an approval on July 3rd this year. While still prioritizing our resources for successful approval and partnering for Orviglance, we also have Oncoral in our portfolio. Oncoral is a tablet formulation of Irinotecan, a well-established intravenous chemotherapeutic agent. A tablet formulation enables a frequent daily low-dose regimen that could offer potential advantages in both efficacy and safety compared to the infrequent, high-dose intravenous administration used today. The opportunity of improving efficacy and safety by administration of daily low doses, also called metronomic dosing, has been demonstrated for Irinotecan and other chemotherapeutic agents. In our phase one studies with Oncoral, we've seen encouraging results that suggest that oral daily administration of Irinotecan could offer meaningful benefits to patients. Importantly, the Oncoral studies have demonstrated an acceptable safety profile, and that the uptake of the drug after oral administration is well suited for a metronomic dosing regimen. This supports the continued development of Oncoral as a daily oral formulation of Irinotecan. Our plan is to bring Oncoral into clinical Phase 2 in gastric cancer. Animal data has demonstrated a synergistic effect of Irinotecan when combined with Lonsurf, another oral cancer treatment already approved for gastric cancer, which makes this all oral combination very interesting. The plan is to demonstrate clinical proof of concept for the combination of Oncoral and Lonsurf in gastric cancer. Our strategy is to start Oncoral development in gastric cancer, which is today a $3 billion market. And Irinotecan is a well-established chemotherapy with recognized anti-tumor effect in many types of solid tumors. And therefore, we see opportunities for developing Oncoral in other indications as well, where daily dosing could positively impact the efficacy and safety outcomes for the patients. And we are assessing these opportunities as part of our ongoing strategic planning of Oncoral. So with that, let's move on to the update on the financials. And I hand it over to Anton. Thank you, Andreas. I will now move to the update on our financials and priorities ahead. In Q4, our operating results amounted to a loss. The costs amounted to 16 million Kroners. The costs are lower in Q4 compared to the costs per quarter in the first half of the year, as well as year over year, and that is due to the completion of the NDA. At the end of December, we had 15 million in liquid assets. In September, we successfully completed a directed share issue, raising 30 million SEK before costs. We now have a cash runway into Q4 2026, well beyond the expected FDA approval date of Orviglance. And to wrap up, we have substantial value creation opportunities ahead, both for Orviglance and Ascelia Pharma. With Orviglance, we are bringing a first-in-class diagnostic drug to market, addressing an $800 million market for patients with a high unmet need. We have two key objectives. One is timely approval of Orviglance. And here we submitted the NDA in early September, which led to its acceptance in mid-November. FDA accepted Orviglance NDA for review, and with a standard ten-month review, we can expect approval early July 2026. And our second objective is to progress Orviglance for commercialization for patients in need. Entering into a commercialization partnership for the launch. And these efforts are continuing to progress. We look forward to continuing our journey with opportunities ahead for growing Ascelia Pharma in 2026 and beyond.

Magnus Corfitzen
17:07 - 17:12

That was our Q4 presentation. Now, we'd like to open up for questions.

Operator
17:13 - 17:23

If you wish to ask a question, please dial Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad.

Maria
17:29 - 17:46

Hello everyone. Thank you for taking the questions. Are you here from DNB? Carnegie? I was wondering. I have two questions for now. So we have approximately five months left until the PDUFA date. Do you have any updates for us on your discussion regarding pricing strategy and maybe payer engagement?

Magnus Corfitzen
17:48 - 17:50

Julie, do you want to take that one?

Julie Waras Brogren
17:51 - 18:43

Yeah. We've, over the years, developed research and insights from payers and experts. And you can say the roadmap for a launch. So we have a comprehensive strategy ready. And we expect a partner to drive the execution of this. But we really have the insights and the strategies in place for a partner to immediately ramp up on that. Does that answer your question?

Yes. The next one is value messages and testing how to approach each partner in each setting and so forth. So it is, yes, an important area. And we have done a lot of preparations.

Maria
18:44 - 19:06

Thank you. Thank you, Julie. And the next one is, so cash runway into the fourth quarter of 2026. But looking ahead, and if we're looking at it optimistically with a potential approval, how would it affect your cost base in the second half of the year? What do you see in front of you?

Magnus Corfitzen
19:06 - 19:35

So, we don't have, you would say, a revenue or cost guidance per se. So what we're saying is that with the current cash we have, and the expected cost going forward, we will have cash into Q4. We will also be very clear that we have a strategy to partner. And as we say, we are optimistic about the outcome of that process, and we think that's going to contribute capital to Ascelia Pharma that will change the outlook.

Maria
19:39 - 19:44

But looking ahead, and if we're looking at it optimistically with a potential approval, how would it affect your cost base in the second half of the year? But looking ahead, and if we're looking at it optimistically with a potential approval, how would it affect your cost base in the second half of the year? That's it for me for now. I'll get back in the queue. What do you see in front of you?

Magnus Corfitzen
19:44 - 19:45

Thank you Maria.

Operator
19:50 - 19:55

And this is your operator speaking. The next speaker is Frederick Thor from Redeye.

Frederick Thor
20:01 - 20:15

Hello. And thank you. Maybe a follow-up to Maria. How will the distribution between R&D costs and administrative costs be for the rest of the year? Roughly.

Magnus Corfitzen
20:18 - 20:29

We don't guide specifically for sort of the split, but I think what you see is probably, with the current outlook, not going to change dramatically.

Frederick Thor
20:31 - 20:46

But looking ahead, and if we're looking at it optimistically with a potential approval, how would it affect your cost base in the second half of the year? But looking ahead, and if we're looking at it optimistically with a potential approval, how would it affect your cost base in the second half of the year? And the next question was about the new patent application for Orviglance that you mentioned or announced. Can you elaborate a bit on this and overall the patent strategy for Orviglance?

Magnus Corfitzen
20:47 - 21:46

Yeah. So happy to talk on that. So we have orphan drug designation in the US, which means that the FDA will grant seven years of market exclusivity for Orviglance, which gives us a very strong protection that we are very satisfied with. So what we also have is we have additional patent applications. It's well established that Manganese enhances MRI signal. So that's not an IP space we can be in, but we have a patent application on the food effect. And we have now filed a patent application related to the manufacturing and how to do that in a good way and control the process. And we have some unique insights that we have filed in the patent. That of course, it's not published yet. So we will not go into details, but we think that was a very nice application that we put in place.

Frederick Thor
21:48 - 22:06

So we will not go into details, but we think that was a very nice application that we put in place. Got it. And a final question in your slide about the addressable market, the rest of the world was quite a bit of the total market. What would you say are the key markets in the rest of the world beyond Europe, Japan, and the US?

Julie Waras Brogren
22:08 - 22:45

Some of the key markets are Asian markets where there is a very mature healthcare system and the awareness about the use of gadolinium and its risks is very high. And there are also other very mature markets in the Middle East and some in Latin America and so forth, where there's a willingness to pay for very vulnerable patients. It's some of the mature markets in Asia, the Middle East, and Latin America primarily.

Frederick Thor
22:48 - 22:50

Got it. That's not an IP space we can be in, but we have a patent application on the food effect. That's all for me.

Julie Waras Brogren
22:52 - 22:52

So.

Operator
22:53 - 22:59

As a reminder, if you wish to ask a question, please dial pound key on your telephone keypad.

Magnus Corfitzen
23:03 - 24:34

Yeah. We also got some questions in the chat here. And we will start. There's a question that points to our strategy of making an agreement with a partner, and it asks what we could share regarding the timeline for that. And I think the question is that we have very clearly committed to securing a partnership agreement with Orviglance. As Julie mentioned, the Day 74 letter and the PDUFA date has certainly been helpful for those conversations. It's a lengthy process. It always is. And especially when we are late stage in development with a lot of data for the partners to review. So I would say we will not say anything specific on the timing. We have a very optimistic outlook on getting a deal done. But if we don't want to put ourselves in a timeline squeeze where that may be exploited by a partner, we don't think that's in the interest of the company. So that's not an IP space we can be in, but we have a patent application on the food effect. So we're dedicated to getting a deal. We're very optimistic on the outlook and things are progressing very well. So I think that's what we can share at this point with our investors; we understand the importance and are fully aligned on that objective with them.

Operator
24:40 - 24:48

There are no more questions at this time. I hand the conference back to the speakers for any written questions and closing comments.

Magnus Corfitzen
24:49 - 26:13

So another question that has come up is that we have mentioned that we are talking to multiple partners. And whether we're still doing that, I think it's fair to say that we are speaking to multiple partners and entertaining those conversations and processes. Again, we are optimistic that we will find a partner. Another question here is whether the European authorities accept an FDA approval or whether we need to do additional studies. So the structure of an application for approval in Europe is very similar to the US application. So, the vast, vast majority of the NDA file can be reused for Europe, but there are some specific European requirements that would need to be adjusted in that submission. And obviously, at the end of the day, it would be the European Medicines Agency. That will make a decision whether any further studies are needed. That's a kind of end of review decision. But we do not expect any additional studies are needed for approval in Europe. Those were the questions. Thank you very much for joining our quarterly call. We look forward to updating you on our progress in 2026. Very excited about the outlook for this year. Thank you and have a good day.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…